Manufacturer Provide High Quality API Raw Material Alogliptin Benzoate CAS 850649-62-6

Introduction

Product Name: Alogliptin benzoate 

Other Name :(R)-2-((6-(3-aMinopiperidin-1-yl)-3-Methyl-2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)Methyl)benzonitrilebenzoate;AlogliptiChemicalbooknbenzoate2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrilebenzoate

CAS NO:850649-62-6

Purity: 99%min
Appearance:White crystalline powder

Molecular formula: C25H27N5O4

MW:461.52

Melting Point :180-182°C

Storage :Keep in dark place,Inert atmosphere,Room temperature

Allogliptin (US trade name: Nesina, European trade name: Vipidia) is an oral DPP-4 inhibitor anti diabetes drug. Alogliptin is the most selective marketed DPPIV inhibition and has similar PK and PD properties compared to previous entries. Like other members of the gliptin family, it almost does not lead to weight gain or no weight gain. The risk of hypoglycemia is relatively small, and it shows relatively mild hypoglycemic activity.

Aloglutinin and other gliptins are usually used in combination with metformin for patients with diabetes that cannot be adequately controlled by metformin alone.

Application

Alogliptin selectively inhibits DPP-4 to reduce the inactivation of glucagon-like peptide 1 (GLP-1) and increase the GLP-1 levels in the body, thus lowering blood sugar. Once blood sugar reaches normal levels, it will cease its sugar-lowering effects, thus effectively reducing the risks of hypoglycemia. Additionally, DPP-4 inhibitor also slows gastric emptying, increases the feeling of fullness, and controls appetite, thus helping patients control their weight.